Journal of Functional Biomaterials· 2026Q2
Marginal Bone Remodeling and Peri-Implant Inflammatory Biomarkers Around Crestally Placed Tissue-Level and Subcrestally Placed Bone-Level Implants: A Prospective Randomized Study
- 0citations
- Q2SCImago
- 2026year
Short summary
Subcrestally placed bone-level (BL) implants showed numerically smaller marginal bone loss (0.29 mm vs 0.55 mm) compared to crestally placed tissue-level (TL) implants after a mean 19.9-month follow-up, though this difference was not statistically significant (p=0.058). No significant differences were found in peri-implant inflammatory biomarkers (IL-1β, MMP-8).
AI-generated from the title and abstract; the full text is not read.
Key points
- Subcrestally placed bone-level (BL) implants showed numerically less marginal bone loss (0.29 mm) than crestally placed tissue-level (TL) implants (0.55 mm) at a mean 19.9-month follow-up.
- The difference in marginal bone loss between BL and TL implants was not statistically significant (p=0.058).
- No significant differences were found in peri-implant crevicular fluid levels of IL-1β and MMP-8 between the two implant types.
- Inflammatory biomarkers were not significantly associated with marginal bone loss in this study.
AI-generated from the title and abstract; the full text is not read.
Abstract
(1) Background: Long-term dental implant performance depends on the interaction between mechanical load distribution and peri-implant tissue response. The influence of implant configuration and vertical placement on marginal bone remodeling and early inflammatory signaling remains unclear. Therefore, the aim of this study was to compare crestally placed tissue-level (TL) and subcrestally placed bone-level (BL) implant configurations regarding marginal bone loss (MBL) and inflammatory biomarkers in the peri-implant crevicular fluid (PICF). (2) Methods: In this prospective randomized trial, 58 implants (29 TL, 29 BL) randomly allocated at the implant level were placed in 30 healthy patients; 42 implants (21 TL, 21 BL) in 23 patients were analysed. TL implants were placed at the crestal level, whereas BL implants were positioned 2 mm subcrestally and restored after 2 months using definitive transepithelial abutments (one-time abutment concept). MBL was assessed radiographically at prosthesis delivery, 6 months after loading and at the final follow-up (12–24 months after loading; mean 19.9 months). PICF was collected 6 months after loading to determine interleukin-1β (IL-1β) and matrix metalloproteinase-8 (MMP-8) levels by enzyme-linked immunosorbent assay (ELISA). Data were analysed with linear mixed-effects models accounting for clustering of implants within patients and for repeated measurements. (3) Results: At the final follow-up, mean MBL was 0.55 mm for TL and 0.29 mm for BL implants; the between-group difference in change (0.26 mm; 95% CI −0.01 to 0.53 mm) was not statistically significant (p = 0.058). No statistically significant differences were detected in IL-1β (p = 0.723) or MMP-8 (p = 0.777) concentrations, and neither biomarker was significantly associated with bone loss after adjustment. (4) Conclusions: Subcrestally placed BL implants restored with a one-abutment–one-time protocol showed numerically, but not significantly, smaller marginal bone loss than crestally placed TL implants, and the magnitude of the difference was of limited clinical relevance. Because the configurations differed in several respects, the results cannot be attributed to implant design alone.
The authors' abstract, as published at the source. Journal of Functional Biomaterials, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Oral Surgery
Oral SurgeryDentistry